A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
about
Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersAdvances in the autologous and allogeneic transplantation strategies for multiple myelomaVenous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis.Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaDose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.Bortezomib in multiple myeloma: systematic review and clinical considerations.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.How we manage autologous stem cell transplantation for patients with multiple myelomaSalvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialA dose-schedule finding design for phase I-II clinical trialsDownregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myelomaA randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCTBortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot study.Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.New developments in conditioning regimens before auto-SCT in multiple myeloma.Bortezomib for previously untreated multiple myeloma.Proteasome inhibitors in multiple myeloma: 10 years later.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.Bortezomib for the treatment of previously untreated multiple myeloma.Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?Not too little, not too much-just right! (Better ways to give high dose melphalan).The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Clinical treatment of newly diagnosed multiple myeloma.Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantationSuitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.Bortezomib for the treatment of multiple myeloma.A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.The evolution of stem-cell transplantation in multiple myeloma.Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical TrialsNumber of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control
P2860
Q26851202-412C1016-7502-4E08-A558-5A9FC57B8FD7Q27014801-160775FB-1613-48E7-AFD6-BA6019CA9AB8Q30251535-6AEEAE11-6949-4153-8958-224F1D7910BCQ30757656-A93EEB4A-8009-4B9E-813D-610199B88AC3Q33586505-D1BEB994-7700-4B95-AB82-7B6EE1DEB1E2Q33648344-9677F94E-C336-4F41-9807-DD5D97685AC7Q33714319-F1FD8D23-07EF-41F6-B5CA-630DF41B8B82Q33982728-BC8F5FFE-747F-480D-BD80-CC27D5C8984CQ34001009-BC0F02DB-EC35-492E-A637-EBECD6E8D492Q34019581-0BD30E46-0A4A-42AF-A4E1-4DCCA532CF92Q36138646-56DF985A-CDFF-43D8-BE9C-782D82B216E4Q36561848-7EA61EB3-E242-4214-BAE3-0A3D3752E1D6Q36803165-B81B9F38-F816-4E37-9651-E3F27EB929A8Q36973229-7ED635B0-4F62-497A-9E1A-B9C710B63C11Q37009725-594AB00C-DE8C-48B0-A5F5-498B634744B8Q37359565-4A332BB6-71DC-4AA5-B2A8-3AB50E5F5AD8Q37848037-826B3BC6-F238-4311-9CB3-EFE65573FFD0Q37908155-29159925-13F1-4C6F-8B52-2379FE21DB36Q38014395-B23D1E90-EE04-47EC-89C5-9F513DC8A7AAQ38095526-C78FFE2A-322F-4BB8-A6D2-00AB8CAC9E8EQ38096055-D99078EE-84E2-46FC-ACE1-E390D18D95B2Q38163027-BD22BF58-8BB1-4792-B159-35533783A04DQ38240941-917570D4-205D-445E-9EA3-8D89BDBC5F0DQ38246060-660E62A9-21F0-40D9-8443-42983BFA0E94Q38578071-D6126BA0-3FBA-4D70-B13C-7A38DF2E29D4Q38877336-0E14038B-A497-4C92-8E65-4FC25281EED8Q39007207-1C8EA520-FF74-4BFE-AD40-DAE091420818Q42907761-7284CAF5-EAD9-40C5-A629-06DF82811A4AQ44647283-3EDA078F-FA1E-4510-9909-B1484DF18A0FQ46251291-0FA85937-BCA2-42C9-9750-47B18383EAA9Q47238436-7428074B-9337-4834-94F5-4C1506383785Q47369825-025655BE-24C2-4DFC-99C8-55A31701E899Q47604607-DF00C11C-A958-4035-9924-7DAEF8C49E05Q50225359-25BB45B8-BC97-4B72-9BAE-F3C8490B9FCDQ52715329-B0AFF6EA-3ACE-4DA7-9685-68F35E9FD931Q52836468-7C6E46C7-17FD-4886-B519-285724D9B115Q52838528-B2C8653C-1935-47E0-A6D1-ED559F8B5D1BQ58910958-BE5991DE-6650-4B0B-A34A-A7DF0E701C68Q58910979-17A83F14-C58D-431F-A629-B5B25C797A9B
P2860
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
A phase I/II trial combining h ...... e- and schedule-finding study.
@en
A phase I/II trial combining h ...... e- and schedule-finding study.
@nl
type
label
A phase I/II trial combining h ...... e- and schedule-finding study.
@en
A phase I/II trial combining h ...... e- and schedule-finding study.
@nl
prefLabel
A phase I/II trial combining h ...... e- and schedule-finding study.
@en
A phase I/II trial combining h ...... e- and schedule-finding study.
@nl
P2093
P1476
A phase I/II trial combining h ...... e- and schedule-finding study.
@en
P2093
Ajay Nooka
Amelia A Langston
Christopher R Flowers
Claire Torre
Edmund K Waller
H Jean Khoury
Heather Renfroe
Jonathan Kaufman
Leonard T Heffner
Mary J Lechowicz
P304
P356
10.1158/1078-0432.CCR-10-1662
P407
P50
P577
2010-08-25T00:00:00Z